ANRO (Alto Neuroscience) Beginning Cash Position: $176.98 Mil (As of Mar. 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $26.48
! 2 Warning Signs
View Full Analysis

What is Alto Neuroscience Beginning Cash Position?

Alto Neuroscience ANRO -4.20% 12 Beginning Cash Position is $176.98 Mil as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Alto Neuroscience's Beginning Cash Position for the quarter that ended in Mar. 2026 was $176.98 Mil.

Alto Neuroscience's quarterly Beginning Cash Position declined from Sep. 2025 ($148.09 Mil) to Dec. 2025 ($138.32 Mil) but then increased from Dec. 2025 ($138.32 Mil) to Mar. 2026 ($176.98 Mil).

Alto Neuroscience's annual Beginning Cash Position increased from Dec. 2023 ($48.34 Mil) to Dec. 2024 ($82.55 Mil) and increased from Dec. 2024 ($82.55 Mil) to Dec. 2025 ($168.73 Mil).

Alto Neuroscience Beginning Cash Position Related Terms

Alto Neuroscience Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience Beginning Cash Position Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
4.01 25.71 48.34 82.55 168.73

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.73 161.25 148.09 138.32 176.98
ANRO
12GF Score
Alto Neuroscience Inc ANRO
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $176.98 Mil mean?
Alto Neuroscience (ANRO) has a Beginning Cash Position of $176.98 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alto Neuroscience and its competitors.
Is Alto Neuroscience's Beginning Cash Position too high?
Alto Neuroscience's current Beginning Cash Position is $176.98 Mil. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Beginning Cash Position compare to SANA and AVTX?
Alto Neuroscience's Beginning Cash Position of $176.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alto Neuroscience and its competitors. Alto Neuroscience's current Beginning Cash Position is $176.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Beginning Cash Position of $176.98 Mil. The current Beginning Cash Position is $176.98 Mil. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Beginning Cash Position is $176.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.48
Price